Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Imatinib and beyond—exploring the full potential of _targeted therapy for CML

Nature Reviews Clinical Oncology volume 6, pages 535–543 (2009)Cite this article

Abstract

A subset of patients with chronic myeloid leukemia (CML) who receive imatinib therapy will require alternative therapy at some point owing to safety reasons or lack of efficacy. Achieving an early response with imatinib is protective against treatment failure; second-generation tyrosine kinase inhibitors (TKIs; for example, nilotinib, dasatinib, bosutinib), however, have proven to be efficacious at restoring cytogenetic responses in patients who require subsequent therapy. Response duration, however, is yet to be established and a considerable proportion of patients fail to achieve a clinically meaningful response. A third generation of TKIs is currently undergoing clinical testing for use in patients who fail imatinib and a second-generation TKI. Most of these agents are multikinase inhibitors with activity against a wide variety of BCR-ABL1 mutations, including the highly resistant T315I. The use of second-generation TKIs in the frontline setting seems to provide higher rates of early response compared with imatinib. If these results are confirmed in randomized studies, nilotinib and dasatinib could replace imatinib as standard frontline therapy in CML. Despite the activity of all of the above mentioned agents, curing CML will ultimately depend on the development of agents capable of vanquishing BCR-ABL1-positive CML stem cells. Efforts aimed at achieving this goal are ongoing.

Key Points

  • The phase III IRIS trial established imatinib as standard therapy for chronic phase CML; an update indicates that a substantial proportion of patients will require alternative therapy during the course of treatment

  • The second-generation tyrosine kinase inhibitors nilotinib and dasatinib can restore cytogenetic response in patients who have failed imatinib therapy; response duration, however, has not been fully established

  • Nilotinib or dasatinib therapy in the frontline setting seems to provide rapid and improved rates of cytogenetic and molecular response, which could potentially translate into improved long-term outcomes

  • Imatinib discontinuation upon achievement of complete molecular response results in high rates of relapse, probably because of the innate insensitivity of CML stem cells to tyrosine kinase inhibitors

  • There is an urgent need to identify pharmacologic inhibitors of pathways essential for the maintenance of BCR-ABL1-positive leukemic initiating cells

  • Several agents with activity against the highly insensitive BCR-ABL1 T315I mutation are being evaluated in clinical trials

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Disease progression during imatinib therapy in the IRIS trial after 7 years of follow-up.

Similar content being viewed by others

References

  1. Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408–2417 (2006).

    Article  CAS  Google Scholar 

  2. O'Brien, S. G. et al. International Randomized Study of Interferon Versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM) [abstract]. Blood 112, 186 (2008).

    Article  Google Scholar 

  3. Hughes, T. P. et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349, 1423–1432 (2003).

    Article  CAS  Google Scholar 

  4. Cortes, J. et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin. Cancer Res. 11, 3425–3432 (2005).

    Article  CAS  Google Scholar 

  5. Quintas-Cardama, A. & Cortes, J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113, 1619–1630 (2009).

    Article  CAS  Google Scholar 

  6. Druker, B. J. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038–1042 (2001).

    Article  CAS  Google Scholar 

  7. Hughes, T. et al. Reduction of BCR-ABL transcript levels at 6, 12, and 18 months (mo) correlates with long-term outcomes on imatinib (IM) at 72 mo: An analysis from the international randomized study of interferon versus STI571 (IRIS) in patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) [abstract]. Blood 11, 334 (2008).

    Google Scholar 

  8. de Lavallade, H. et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J. Clin. Oncol. 26, 3358–3363 (2008).

    Article  Google Scholar 

  9. Press, R. D. et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin. Cancer Res. 13, 6136–6143 (2007).

    Article  CAS  Google Scholar 

  10. Branford, S. et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin. Cancer Res. 13, 7080–7085 (2007).

    Article  CAS  Google Scholar 

  11. Iacobucci, I. et al. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. J. Clin. Oncol. 24, 454–459 (2006).

    Article  CAS  Google Scholar 

  12. Guilhot, F. et al. Time to complete cytogenetic response (CCyR) does not affect long-term outcomes for patients on imatinib therapy [abstract]. Blood 110, 27 (2007).

    Google Scholar 

  13. Quintas-Cardama, A., Kantarjian, H. & Cortes, J. Tyrosine kinase inhibitors for chronic myelogenous leukemia. N. Engl. J. Med. 357, 1557 (2007).

    CAS  PubMed  Google Scholar 

  14. Quintas-Cardama, A. et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myelogenous leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 113, 6315–6321 (2009).

    Article  CAS  Google Scholar 

  15. Kantarjian, H. et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103, 2873–2878 (2004).

    Article  CAS  Google Scholar 

  16. Cortes, J. et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 102, 83–86 (2003).

    Article  CAS  Google Scholar 

  17. Hughes, T. P. et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 112, 3965–3973 (2008).

    Article  CAS  Google Scholar 

  18. Larson, R. A. et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111, 4022–4028 (2008).

    Article  CAS  Google Scholar 

  19. Picard, S. et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109, 3496–3499 (2007).

    Article  CAS  Google Scholar 

  20. Guilhot, F. et al. Imatinib (IM) pharmacokinetic (PK) exposure and its correlation with clinical outcome in patients with chronic-phase chronic myeloid leukemia (CML-CP) for 400 mg and 800 mg daily doses (Tyrosine Kinase Dose Optimization Study [TOPS]) [abstract]. Blood 112, 447 (2008).

    Article  Google Scholar 

  21. Ault, P. et al. Clinical use of imatinib plasma levels in patients with chronic myeloid leukemia (CML) [abstract]. Blood 112, 4255 (2008).

    Google Scholar 

  22. Cortes, J. et al. A phase III, randomized, open-label study of 400 mg versus 800 mg of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints: 1-year results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) study [abstract]. Blood 112, 335 (2008).

    Google Scholar 

  23. Baccarani, M. et al. Cytogenetic and molecular response to imatinib in high risk (Sokal) chronic myeloid leukemia (CML): results of an European Leukemianet prospective study comparing 400 mg and 800 mg front-line [abstract]. Blood 112, 185 (2008).

    Google Scholar 

  24. Rosti, G. et al. High and early rates of cytogenetic and molecular response with nilotinib 800 mg daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: results of a phase 2 trial of the GIMEMA CML Working Party [abstract]. Blood 112, 181 (2008).

    Google Scholar 

  25. Cortes, J. et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP) [abstract]. Blood 112, 182 (2008).

    Google Scholar 

  26. Cortes, J. et al. Efficacy of nilotinib (formerly AMN107) in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP) [abstract]. Blood 112, 446 (2008).

    Google Scholar 

  27. Holtz, M. S., Forman, S. J. & Bhatia, R. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia 19, 1034–1041 (2005).

    Article  CAS  Google Scholar 

  28. Holtz, M. S. et al. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 99, 3792–3800 (2002).

    Article  CAS  Google Scholar 

  29. Graham, S. M. et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319–325 (2002).

    Article  CAS  Google Scholar 

  30. Rousselot, P. et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109, 58–60 (2007).

    Article  CAS  Google Scholar 

  31. Mahon, F. et al. Is it possible to stop imatinib in patients with chronic myeloid leukemia? An update from a French pilot study and first results from the multicentre 'Stop Imatinib' (STIM) study [abstract]. Blood 112, 187 (2008).

    Google Scholar 

  32. Verma, D., Kantarjian, H., Jain, N. & Cortes, J. Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha. Leuk. Lymphoma 49, 1399–1402 (2008).

    Article  Google Scholar 

  33. Copland, M. et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 111, 2843–2853 (2008).

    Article  CAS  Google Scholar 

  34. Strauss, A. et al. Effective induction of apoptosis in chronic myeloid leukemia CD34+ cells by the histone deacetylase inhibitor LAQ824 in combination with imatinib [abstract]. Blood 110, 1031 (2007).

    Google Scholar 

  35. Ito, K. et al. PML _targeting eradicates quiescent leukaemia-initiating cells. Nature 453, 1072–1078 (2008).

    Article  CAS  Google Scholar 

  36. Zhao, C. et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458, 776–779 (2009).

    Article  CAS  Google Scholar 

  37. Bradeen, H. A. et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108, 2332–2338 (2006).

    Article  CAS  Google Scholar 

  38. Quintas-Cardama, A., Kantarjian, H. & Cortes, J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat. Rev. Drug Discov. 6, 834–848 (2007).

    Article  CAS  Google Scholar 

  39. Carter, T. A. et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl Acad. Sci. USA 102, 11011–11016 (2005).

    Article  CAS  Google Scholar 

  40. Cortes, J. et al. Preliminary clinical activity in a phase I trial of the BCR-ABL/IGF-1R/aurora kinase inhibitor XL228 in patients with Ph+ leukemias with either failure to multiple TKI therapies or with T315I mutation [abstract]. Blood 112, 3232 (2008).

    Google Scholar 

  41. Paquette, R. et al. PHA-739358, an aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL. Blood 110, 1030 (2007).

    Google Scholar 

  42. Van Etten, R. A. et al. Switch pocket inhibitors of the ABL tyrosine kinase: distinct kinome inhibition profiles and in vivo efficacy in mouse models of CML and B-lymphoblastic leukemia induced by BCR-ABL T315I [abstract]. Blood 112, 576 (2008).

    Article  Google Scholar 

  43. Kantarjian, H. M. et al. Homoharringtonine: history, current research, and future direction. Cancer 92, 1591–1605 (2001).

    Article  CAS  Google Scholar 

  44. Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P. & Craig, R. W. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc. Natl Acad. Sci. USA 90, 3516–3520 (1993).

    Article  CAS  Google Scholar 

  45. Tang, R. et al. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol. Cancer Ther. 5, 723–731 (2006).

    Article  CAS  Google Scholar 

  46. Chen, Y. et al. Inhibitory effects of homoharringtonine on leukemic stem cells and BCR-ABL induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice [abstract]. Blood 110, 2912 (2007).

    Google Scholar 

  47. Cortes, J. et al. Safety and efficacy of subcutaneous (SC) omacetaxine mepesuccinate in imatinib(IM)-resistant chronic myeloid leukemia (CML) patients (pts) with the T315I mutation—results of an ongoing multicenter phase II study [abstract]. Blood 112, 3239 (2008).

    Google Scholar 

  48. Hochhaus, A. et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22, 1200–1206 (2008).

    Article  CAS  Google Scholar 

  49. Guilhot, F. et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109, 4143–4150 (2007).

    Article  CAS  Google Scholar 

  50. Cortes, J. et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 22, 2176–2183 (2008).

    Article  CAS  Google Scholar 

  51. Kantarjian, H. et al. Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study [abstract]. Blood 112, 3238 (2008).

    Google Scholar 

  52. Le Coutre, P. et al. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study [abstract]. Blood 112, 3229 (2008).

    Google Scholar 

  53. Giles, F. et al. Nilotinib (Tasigna) in pts with Ph+ CML-BC who are resistant or intolerant to imatinib [abstract]. Blood 110, 1025 (2007).

    Article  Google Scholar 

  54. Cortes, J. et al. Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib [abstract]. Blood 112, 1098 (2008).

    Google Scholar 

  55. Gambacorti-Passerini, C. et al. Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated in patients with AP and BP CML and Ph+ ALL [abstract]. Blood 112, 1101 (2008).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

    Alfonso Quintás-Cardama, Hagop Kantarjian & Jorge Cortes

Authors
  1. Alfonso Quintás-Cardama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hagop Kantarjian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jorge Cortes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jorge Cortes.

Ethics declarations

Competing interests

J. Cortes declares he receives grant/research support from BMS, Novartis, and Wyeth. The other authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Quintás-Cardama, A., Kantarjian, H. & Cortes, J. Imatinib and beyond—exploring the full potential of _targeted therapy for CML. Nat Rev Clin Oncol 6, 535–543 (2009). https://doi.org/10.1038/nrclinonc.2009.112

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2009.112

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing
  NODES
INTERN 3
Note 1
twitter 1